Biorelate

Biorelate is a pioneering AI and machine learning-driven company specialising in biomedical data curation. Founded in Manchester, UK, Biorelate transforms vast, unstructured biomedical data into actionable insights, enabling pharmaceutical and life sciences organisations to improve the efficiency and success of their drug discovery processes. By leveraging cutting-edge natural language processing (NLP) and machine learning technologies, Biorelate curates complex biomedical data, addressing critical inefficiencies in the pharmaceutical sector.

With a growing client base that includes top 5 global pharmaceutical companies, Biorelate’s innovative solutions empower researchers and organisations to streamline R&D, reduce costs, and accelerate time-to-market for groundbreaking treatments.

YFM Equity Partners identified Biorelate as a disruptive force in the rapidly expanding pharmaceutical AI sector. The company’s ability to address one of the industry’s key challenges—effectively curating unstructured biomedical data—positions it as a leader in this space.

YFM’s initial investment in November 2022 was driven by Biorelate’s potential to revolutionise drug discovery through its advanced AI capabilities. The decision to provide follow-on funding in 2024 reflects confidence in Biorelate’s growth trajectory and its ability to scale further within the global pharmaceutical market.

YFM identified Biorelate as a disruptive force in the rapidly expanding pharmaceutical AI sector. The company’s ability to address one of the industry’s key challenges—effectively curating unstructured biomedical data—positions it as a leader in this space.

YFM’s initial investment in November 2022 was driven by Biorelate’s potential to revolutionise drug discovery through its advanced AI capabilities. The decision to provide follow-on funding in 2024 reflects confidence in Biorelate’s growth trajectory and its ability to scale further within the global pharmaceutical market.

Growth and Achievements
Since YFM’s initial investment, Biorelate has made remarkable progress:

• Revenue Growth: Annual recurring revenue (ARR) has doubled, supported by the addition of top-tier pharmaceutical clients.
• Pipeline Development: Strengthened its pipeline with advanced opportunities among existing clients, building a strong foundation for future growth.
• Expanded U.S. Presence: Deepened its footprint within the U.S. market, leveraging its scalable business model and increased resources.

Future Outlook
With continued backing from YFM and other investors, Biorelate is poised to capitalise on the pharmaceutical sector’s growing adoption of AI technologies. The company’s strategic priorities include:

• Scaling Operations: Expanding its team and infrastructure to meet increasing demand from large pharmaceutical clients.
• Broadening Offerings: Developing solutions for a wider range of R&D applications, further diversifying its product portfolio.
• International Growth: Continuing to expand within the U.S. and exploring additional global opportunities.

By addressing the inefficiencies of traditional biomedical research processes, Biorelate is transforming how the pharmaceutical industry approaches drug discovery. With its advanced AI-driven solutions and a clear growth strategy, the company is well-positioned to lead the next wave of innovation in the life sciences sector.